Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment

Journal of Hypertension

Volumn 29, Issue 11, 2011, Pages 2138-2146

  Krop, Manne ^a   Van Gool, Jeanette M G ^a   Day, Duane ^b   Hollenberg, Norman K ^c   Danser, Alexander H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Molecular Innovations   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

aliskiren; diabetes; ELISA; irbesartan; prorenin

Indexed keywords

ALISKIREN; CAPTOPRIL; IRBESARTAN; MONOCLONAL ANTIBODY; PRORENIN; RENIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; IMMUNORADIOMETRIC ASSAY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE;

EID: 80054095029     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834b1978     Document Type: Article

References (28)

1. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé C, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007; 25:2441-2453. (Pubitemid 350060383)
2. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005; 46:1069-1076. (Pubitemid 41533004)
3. Krop M, Danser AHJ. Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. Curr Hyp Rep 2008; 10:112-118.
4. Krop M, de Bruyn JHB, Derkx FHM, Danser AHJ. Renin and prorenin disappearance in humans postnephrectomy: evidence for binding? Front Biosci 2008; 13:3931-3939. (Pubitemid 351594671)
5. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312:1412-1417. (Pubitemid 15083658)
6. Derkx FHM, Alberda AT, de Jong FH, Zeilmaker FH, Makovitz JW, SchalekampMADH. Source of plasma prorenin in early and late pregnancy: observations in a patient with primary ovarian failure. J Clin Endocrinol Metab 1987; 65:349-354. (Pubitemid 17103023)
7. Sealey JE, McCord D, Taufield PA, Ales KA, Druzin ML, Atlas SA, Laragh JH. Plasma prorenin in first-trimester pregnancy: relationship to changes in human chorionic gonadotropin. Am J Obstet Gynecol 1985; 153:514-519. (Pubitemid 16218447)
8. Deinum J, Ronn B, Mathiesen E, Derkx FHM, Hop WC, Schalekamp MADH. Increaseinserumproreninprecedesonsetofmicroalbuminuriainpatientswith insulin-dependent diabetes mellitus. Diabetologia 1999; 42:1006-1010.
9. Danser AHJ. Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc Pharmacol 2007; 50:105-111. (Pubitemid 47267735)
10. Danser AHJ, Derkx FHM, Schalekamp MADH, Hense HW, Riegger GAJ, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998; 16:853-862. (Pubitemid 28247969)
11. Deinum J, Derkx FHM, Schalekamp MADH. Improved immunoradiometric assay for plasma renin. Clin Chem 1999; 45:847-854. (Pubitemid 29266615)
12. Campbell DJ, Nussberger J, Stowasser M, Danser AHJ, Morganti A, Frandsen E, Mé nard J. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009; 55:867-877.
13. Schalekamp MADH, Derkx FHM, Deinum J, Danser AHJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens 2008; 26:928-937. (Pubitemid 351520980)
14. Mercure C, Thibault G, Lussier-Cacan S, Davignon J, Schiffrin EL, Reudelhuber TL. Molecular analysis of human prorenin prosegment variants in vitro and in vivo. J Biol Chem 1995; 270:16355-16359.
15. Derkx FHM, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MADH. Nonproteolytic 'activation' of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. J Biol Chem 1992; 267:22837-22842.
16. Saris JJ, Derkx FHM, de Bruin RJA, Dekkers DHW, Lamers JMJ, Saxena PR, et al. High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol 2001; 280:H1706-H1715.
17. BatenburgWW, de Bruin RJA, van Gool JMG, Mü ller DN, Bader M, Nguyen G, Danser AHJ. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1151-1157.
18. Admiraal PJJ, van Kesteren CAM, Danser AHJ, Derkx FHM, Sluiter W, Schalekamp MADH. Uptake and proteolytic activation of prorenin by cultured human endothelial cells. J Hypertens 1999; 17:621-629. (Pubitemid 29243494)
19. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20:587-597. (Pubitemid 46678721)
20. Krop M, Garrelds IM, de Bruin RJA, van Gool JMG, Fisher NDL, Hollenberg NK, Danser AHJ. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008; 52:1076-1083.
21. Mé nard J, Guyene TT, Peyrard S, Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006; 24:529-534.
22. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32:1873-1879.
23. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010; 53:1576-1580.
24. Fisher NDL, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117:3199-3205.
25. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39:E1-E8.
26. Schweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. Physiology 2007; 22:310-319.
27. Derkx FHM, de Bruin RJA, van Gool JM, van den Hoek MJ, Beerendonk CC, Rosmalen F, et al. Clinical validation of renin monoclonal antibodybased sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996; 42:1051-1063. (Pubitemid 26231411)
28. Galen FX, Devaux C, Guyenne T, Mé nard J, Corvol P. Multiple forms of human renin. Purification and characterization. J Biol Chem 1979; 254:4848-4855. (Pubitemid 9204191)